Momenta Pharmaceuticals, Inc. (MNTA)

[mouton29]

<<mouton....I am referring to M copax....not M enox.

the M copax split is supposed to be MNTA stronger than the M enox. >>

Sorry, I read your post too quickly. I believe that Copaxone is part of the 2006 agreement with Sandoz and there is a simple 50-50 profit share. From the 2006 press release:

The two companies will jointly develop, manufacture and commercialize all of these candidates, and share the profits from the sales of all products under separate profit share arrangements for each product, including an equal profit split specifically on the product candidate from Momenta's pipeline.

http://ir.momentapharma.com/releasedetail.cfm?ReleaseID=243107

This is consistent with their latest 10-Q, which says this:

In 2006 and 2007, we entered into a series of agreements, including a Stock Purchase Agreement and an Investor Rights Agreement, each with Novartis Pharma AG, and a collaboration and license agreement, or the Definitive Agreement, with Sandoz AG, an affiliate of Novartis Pharma AG. Together, this series of agreements is referred to as the 2006 Sandoz Collaboration. Under the Definitive Agreement, we and Sandoz AG jointly develop, manufacture and commercialize M356.

http://sec.gov/Archives/edgar/data/1235010/000110465911044121/a11-13885_110q.htm